Hyperparathyroidism, Primary
18
2
2
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
1 terminated out of 18 trials
91.7%
+5.2% vs benchmark
17%
3 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (18)
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Primary Hyperparathyroidism and Gut Microbiota
Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
Parathyroid Adenoma Detection With Rubidium-82 Imaging
WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making
Autofluorescence in Surgery for Primary Hyperparathyroidism
FCH PET/MRI Parathyroid Localization
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism
Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment
18F-Fluorocholine for the Detection of Parathyroid Adenomas
Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.
Study on the Use of Cinacalcet in Phosphocalcic Context.
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)